Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype

Oncogene volume 36, pages 4224–4232 (2017)Cite this article

Subjects

Abstract

Diffuse large B-cell lymphoma (DLBCL) has been categorized into two molecular subtypes that have prognostic significance, namely germinal center B-cell like (GCB) and activated B-cell like (ABC). Although ABC-DLBCL has been associated with NF-κB activation, the relationships between activation of specific NF-κB signals and DLBCL phenotype remain unclear. Application of novel gene expression classifiers identified two new DLBCL categories characterized by selective p100 (NF-κB2) and p105 (NF-κB1) signaling. Interestingly, our molecular studies showed that p105 signaling is predominantly associated with GCB subtype and histone mutations. Conversely, most tumors with p100 signaling displayed ABC phenotype and harbored ABC-associated mutations in genes such as MYD88 and PIM1. In vitro, MYD88 L265P mutation promoted p100 signaling through TAK1/IKKα and GSK3/Fbxw7a pathways, suggesting a novel role for this protein as an upstream regulator of p100. p100 signaling was engaged during activation of normal B cells, suggesting p100’s role in ABC phenotype development. Additionally, silencing p100 in ABC-DLBCL cells resulted in a GCB-like phenotype, with suppression of Blimp, IRF4 and XBP1 and upregulation of BCL6, whereas introduction of p52 or p100 into GC cells resulted in differentiation toward an ABC-like phenotype. Together, these findings identify specific roles for p100 and p105 signaling in defining DLBCL molecular subtypes and posit MYD88/p100 signaling as a regulator for B-cell activation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66: 443–459.

    Article  PubMed  Google Scholar 

  2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.

    Article  CAS  PubMed  Google Scholar 

  3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.

    Article  PubMed  Google Scholar 

  4. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RCT et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74.

    Article  CAS  PubMed  Google Scholar 

  5. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q et al. Mutations of multiple genes cause deregulation of NF-[kgr]B in diffuse large B-cell lymphoma. Nature 2009; 459: 717–721.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Zhang B, Calado Dinis P, Wang Z, Fröhler S, Köchert K, Qian Y et al. An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression. Cell Rep 2015; 11: 715–726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gasparini C, Celeghini C, Monasta L, Zauli G . NF-κB pathways in hematological malignancies. Cell Mol Life Sci 2014; 71: 2083–2102.

    Article  CAS  PubMed  Google Scholar 

  8. Luo J-L, Kamata H, Karin M . IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy. J Clin Invest 2005; 115: 2625–2632.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Oeckinghaus A, Hayden MS, Ghosh S . Crosstalk in NF-κB signaling pathways. Nat Immunol 2011; 12: 695–708.

    Article  CAS  PubMed  Google Scholar 

  10. Ramachandiran S, Adon A, Guo X, Wang Y, Wang H, Chen Z et al. Chromosome instability in diffuse large B cell lymphomas is suppressed by activation of the noncanonical NF-κB pathway. Int J Cancer 2014; 136: 2341–2351.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Sha WC, Liou H-C, Tuomanen EI, Baltimore D . Targeted disruption of the p50 subunit of NF-κB leads to multifocal defects in immune responses. Cell 1995; 80: 321–330.

    Article  CAS  PubMed  Google Scholar 

  12. Bernal-Mizrachi L, Lovly CM, Ratner L . The role of NF-κB-1 and NF-κB-2-mediated resistance to apoptosis in lymphomas. PNAS 2006; 103: 9220–9225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 3701–3713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Thompson MP, Aggarwal BB, Shishodia S, Estrov Z, Kurzrock R . Autocrine lymphotoxin production in Epstein-Barr virus-immortalized B cells: induction via NF-κB activation mediated by EBV-derived latent membrane protein 1. Leukemia 2003; 17: 2196–2201.

    Article  CAS  PubMed  Google Scholar 

  15. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TFE et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354: 2419–2430.

    Article  CAS  PubMed  Google Scholar 

  16. McCool KW, Miyamoto S . DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunol Rev 2012; 246: 311–326.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B . Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65: 264–276.

    CAS  PubMed  Google Scholar 

  18. Davis RE, Brown KD, Siebenlist U, Staudt LM . Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 1861–1874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313–2323.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci 2013; 110: 1398–1403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.

    Article  CAS  PubMed  Google Scholar 

  22. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RSK, Kuppers R et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001; 412: 341–346.

    Article  CAS  PubMed  Google Scholar 

  23. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci 2012; 109: 3879–3884.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181–185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lenz G, Staudt LM . Aggressive lymphomas. N Engl J Med 2010; 362: 1417–1429.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Shaffer AL, Young RM, Staudt LM . Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012; 30: 565–610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Shaffer 3rd AL, Young RM, Staudt LM . Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012; 30: 565–610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Klein U, Dalla-Favera R . Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8: 22–33.

    Article  CAS  PubMed  Google Scholar 

  29. Bowles JA, Wang S-Y, Link BK, Allan B, Beuerlein G, Campbell M-A et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108: 2648–2654.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lepin EJM, Bastin JM, Allan DSJ, Roncador G, Braud VM, Mason DY et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000; 30: 3552–3561.

    Article  CAS  PubMed  Google Scholar 

  31. Navarro F, Llano M, Bellón T, Colonna M, Geraghty DE, López-Botet M . The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells. Eur J Immunol 1999; 29: 277–283.

    Article  CAS  PubMed  Google Scholar 

  32. Chang H, Schimmer AD . Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy. Mol Cancer Ther 2007; 6: 24–30.

    Article  CAS  PubMed  Google Scholar 

  33. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ . RASSF4/AD037 is a potential Ras effector/tumor suppressor of the RASSF family. Cancer Res 2004; 64: 8688–8693.

    Article  CAS  PubMed  Google Scholar 

  34. Wu RP, Hayashi T, Cottam HB, Jin G, Yao S, Wu CCN et al. Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci 2010; 107: 7479–7484.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K, Mundel P . Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 2006; 8: 485–491.

    Article  CAS  PubMed  Google Scholar 

  36. Hale JS, Frock RL, Mamman SA, Fink PJ, Kennedy BK . Cell-extrinsic defective lymphocyte development in Lmna-/- mice. PLoS ONE 2010; 5: e10127.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Liao Y-C, Si L, de Vere White RW, Lo SH . The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol 2007; 176: 43–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Roodink I, Kats G, van Kempen L, Grunberg M, Maass C, Verrijp K et al. Semaphorin 3E expression correlates inversely with plexin D1 during tumor progression. Am J Pathol 2008; 173: 1873–1881.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Chan YW, Fava LL, Uldschmid A, Schmitz MHA, Gerlich DW, Nigg EA et al. Mitotic control of kinetochore-associated dynein and spindle orientation by human spindly. J Cell Biol 2009; 185: 859–874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. De Antoni A, Pearson CG, Cimini D, Canman JC, Sala V, Nezi L et al. The Mad1/Mad2 complex as a template for Mad2 activation in the spindle assembly checkpoint. Curr Biol 2005; 15: 214–225.

    Article  CAS  PubMed  Google Scholar 

  41. Loïodice I, Alves A, Rabut G, van Overbeek M, Ellenberg J, Sibarita J-B et al. The entire Nup107-160 complex, including three new members, is targeted as one entity to kinetochores in mitosis. Mol Biol Cell 2004; 15: 3333–3344.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Roman Y, Oshige M, Lee Y-J, Goodwin K, Georgiadis MM, Hromas RA et al. Biochemical characterization of a SET and transposase fusion protein, metnase: its DNA binding and DNA cleavage activity. Biochemistry 2007; 46: 11369–11376.

    Article  CAS  PubMed  Google Scholar 

  43. Wolf A, Keil R, Gotzl O, Mun A, Schwarze K, Lederer M et al. The armadillo protein p0071 regulates Rho signalling during cytokinesis. Nat Cell Biol 2006; 8: 1432–1440.

    Article  CAS  PubMed  Google Scholar 

  44. Zhu H, Coppinger JA, Jang C-Y, Yates JR, Fang G . FAM29A promotes microtubule amplification via recruitment of the NEDD1–γ-tubulin complex to the mitotic spindle. J Cell Biol 2008; 183: 835–848.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Chattopadhyay S, Bielinsky A-K . Human Mcm10 regulates the catalytic subunit of DNA polymerase-α and prevents DNA damage during replication. Mol Biol Cell 2007; 18: 4085–4095.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Klon AE, Héroux A, Ross LJ, Pathak V, Johnson CA, Piper JR et al. Atomic structures of human dihydrofolate reductase complexed with NADPH and two lipophilic antifolates at 1.09 a and 1.05 a resolution. J Mol Biol 2002; 320: 677–693.

    Article  CAS  PubMed  Google Scholar 

  47. Nandi AK, Ford T, Fleksher D, Neuman B, Rapoport AP . Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein–protein interaction with tumor suppressor p53. Biochem Biophys Res Commun 2007; 358: 181–188.

    Article  CAS  PubMed  Google Scholar 

  48. Nijman SMB, Huang TT, Dirac AMG, Brummelkamp TR, Kerkhoven RM, D'Andrea AD et al. The deubiquitinating enzyme USP1 regulates the fanconi anemia pathway. Mol Cell 2005; 17: 331–339.

    Article  CAS  PubMed  Google Scholar 

  49. Piao L, Nakagawa H, Ueda K, Chung S, Kashiwaya K, Eguchi H et al. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage. Genes Chromosomes Cancer 2011; 50: 13–24.

    Article  CAS  PubMed  Google Scholar 

  50. Dephoure N, Zhou C, Villén J, Beausoleil SA, Bakalarski CE, Elledge SJ et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci 2008; 105: 10762–10767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Joshi B, Cameron A, Jagus R . Characterization of mammalian eIF4E-family members. Eur J Biochem 2004; 271: 2189–2203.

    Article  CAS  PubMed  Google Scholar 

  52. Kaser A, Bogengruber E, Hallegger M, Doppler E, Lepperdinger G, Jantsch M et al. Brix from Xenopus laevis and Brx1p from yeast define a new family of proteins involved in the biogenesis of large ribosomal subunits. Biol Chem 2001; 382: 1637–1647.

    Article  CAS  PubMed  Google Scholar 

  53. Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, Ho W et al. Unravelling the complexities of the NF-κB signalling pathway using mouse knockout and transgenic models. Oncogene 2006; 25: 6781–6799.

    Article  CAS  PubMed  Google Scholar 

  54. Basak S, VF-S Shih, Hoffmann A . Generation and activation of multiple dimeric transcription factors within the NF-κB signaling system. Mol Cell Biol 2008; 28: 3139–3150.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C et al. The lymphotoxin-β receptor induces different patterns of gene expression via two NF-κB pathways. Immunity 2002; 17: 525–535.

    Article  CAS  PubMed  Google Scholar 

  56. Shih VF-S, Tsui R, Caldwell A, Hoffmann A . A single NFκB system for both canonical and non-canonical signaling. Cell Res 2011; 21: 86–102.

    Article  CAS  PubMed  Google Scholar 

  57. Zhao B, Barrera Luis A, Ersing I, Willox B, Schmidt Stefanie CS, Greenfeld H et al. The NF-κB genomic landscape in lymphoblastoid B cells. Cell Rep 2014; 8: 1595–1606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol 2012; 25: 651–660.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Harvey D, Pointon JJ, Karaderi T, Appleton LH, Farrar C, Wordsworth BP . A common functional variant of endoplasmic reticulum aminopeptidase 2 (ERAP2) that reduces major histocompatibility complex class I expression is not associated with ankylosing spondylitis. Rheumatology 2011; 50: 1720–1721.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Kamphausen E, Kellert C, Abbas T, Akkad N, Tenzer S, Pawelec G et al. Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. Cancer Immunol Immunother 2010; 59: 1273–1284.

    Article  CAS  PubMed  Google Scholar 

  61. Zhu D, Ikpatt OF, Dubovy SR, Lossos C, Natkunam Y, Chapman-Fredricks JR et al. Molecular and genomic aberrations in chlamydophila psittaci negative ocular adnexal marginal zone lymphomas. Am J Hematol 2013; 88: 730–735.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298–303.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Angus SP, Nevins JR . A role for mediator complex subunit MED13L in Rb/E2F-induced growth arrest. Oncogene 2012; 31: 4709–4717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Marill J, Cresteil T, Lanotte M, Chabot GG . Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 2000; 58: 1341–1348.

    Article  CAS  PubMed  Google Scholar 

  65. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S-i et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011; 13: 170–182.

    Article  CAS  PubMed  Google Scholar 

  66. Ansell SM, Hodge LS, Secreto FJ, Manske M, Braggio E, Price-Troska T et al. Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma. Blood Cancer J 2014; 4: e183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Gerondakis S, Siebenlist U . Roles of the NF-κB pathway in lymphocyte development and function. Cold Spring Harb Perspect Biol 2010; 2: a000182.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A et al. Mice deficient in nuclear factor (NF)-κ B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 1998; 187: 147–159.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Lo JC, Basak S, James ES, Quiambo RS, Kinsella MC, Alegre M-L et al. Coordination between NF-κB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues. Blood 2006; 107: 1048–1055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Claudio E, Brown K, Park S, Wang H, Siebenlist U . BAFF-induced NEMO-independent processing of NF-κB2 in maturing B cells. Nat Immunol 2002; 3: 958–965.

    Article  CAS  PubMed  Google Scholar 

  71. Staudt LM . Oncogenic activation of NF-κB. Cold Spring Harb Perspect Biol 2010; 2: a000109.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Zhang B, Wang Z, Li T, Tsitsikov EN, Ding H-F . NF-κB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 2007; 110: 743–751.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Dr Sagar Lonial and Dr Jing Chen for their critical review and helpful comments. We thank Dr Anne J Novak for providing the L265P MYD88 lentivirus. CRF was supported by NIH (R21 CA158686 and K24 CA208132) and GCCDSW. ISL by the NIH (CA109335 and CA122105) and the Dwoskin and Rizzo Family and Fidelity. JK was supported by GCCDSW. LHB received funding support from the NIH (CA127910 and CA129968) and a GCCDSW. LB-M received funding from the Byron Davis Research Fund.

Author information

Author notes

  1. X Guo and J L Koff: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA

    X Guo, J L Koff, M Cinar, S Ramachandiran, H J Khoury, W Harris, C R Flowers, L H Boise, J Kowalski & L Bernal-Mizrachi

  2. Department of Medicine, Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC, USA

    A B Moffitt & S S Dave

  3. Department of Biostatistics and Bioinformatics, Winship Cancer Institute of Emory University, Atlanta, GA, USA

    Z Chen, J M Switchenko & J Kowalski

  4. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA

    M Mosunjac, S G Neill, K P Mann & M Bagirov

  5. Department of Pharmacology, Emory University, Atlanta, GA, USA

    Y Du

  6. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

    Y Natkunam

  7. Department of Radiation Oncology, Emory University, Atlanta, GA, USA

    M R Rossi

  8. Division of Hematology Oncology and Molecular and Cellular Pharmacology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

    I S Lossos

Authors
  1. X Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J L Koff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A B Moffitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Cinar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Ramachandiran
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J M Switchenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Mosunjac
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S G Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K P Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Bagirov
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Y Du
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Y Natkunam
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. H J Khoury
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M R Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. W Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C R Flowers
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. I S Lossos
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. L H Boise
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. S S Dave
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. J Kowalski
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. L Bernal-Mizrachi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Bernal-Mizrachi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, X., Koff, J., Moffitt, A. et al. Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype. Oncogene 36, 4224–4232 (2017). https://doi.org/10.1038/onc.2017.90

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2017.90

This article is cited by

Search

Advanced search

Quick links